<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04607135</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00106093</org_study_id>
    <nct_id>NCT04607135</nct_id>
  </id_info>
  <brief_title>ARFI Imaging for Targeted Prostate Biopsy</brief_title>
  <official_title>Acoustic Radiation Force Impulse (ARFI) Imaging for Targeted Prostate Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a new ultrasound technique. This technique may&#xD;
      provide additional and improved information about the stiffness and sizes of the internal&#xD;
      structures of your prostate in order to improve the guidance for a targeted biopsy. The&#xD;
      investigational, custom-designed probe and needle guide will be used to produce images of&#xD;
      your prostate and provide guidance for up to 4 additional biopsy samples (cores) prior to a&#xD;
      standard magnetic resonance (MR) ultrasound fusion biopsy procedure. Above the time required&#xD;
      for the MR ultrasound fusion biopsy, this study will take up to 30 additional minutes of time&#xD;
      for collection of the investigational device guided collection of biopsy samples Risks of&#xD;
      participation include increased time under anesthesia (to collect additional biopsies) and&#xD;
      slight heating of tissue.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2021</start_date>
  <completion_date type="Anticipated">April 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 23, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCa detection rate</measure>
    <time_frame>Up to 30 mins</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of cancerous tissue</measure>
    <time_frame>Up to 30 mins</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of cancerous tissue</measure>
    <time_frame>Up to 30 mins</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gleason score</measure>
    <time_frame>Up to 30 mins</time_frame>
    <description>A commonly used method to classify how cells appear in cancerous tissues; the less the cancerous cells look like normal cells, the more malignant the cancer; two numbers, each from 1 to 5, are assigned to the two most predominant types of cells present. These two numbers are added together to produce the Gleason score. Higher numbers indicate more aggressive cancers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gleason Grade Group</measure>
    <time_frame>Up to 30 mins</time_frame>
    <description>A newer technique to stratify prostate cancer risk, 5 categories.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant disease (CSD) as measured by biopsy score.</measure>
    <time_frame>Up to 30 mins</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Acoustic radiation force impulse (ARFI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MR-ultrasound fusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acoustic radiation force impulse (ARFI)</intervention_name>
    <description>Sound waves are sent in a series and are expected to &quot;push on&quot; the prostate and move it a very small amount (the width of a hair). The stiffer the structure (prostate), the less it will move. This motion will be detected by the ultrasound system</description>
    <arm_group_label>Acoustic radiation force impulse (ARFI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Standard ultrasound imaging session, ultrasound sound waves are sent into the tissue and bounce off of structures to make an image that appears on a screen</description>
    <arm_group_label>MR-ultrasound fusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men who are scheduled to undergo ultrasound fusion-MR prostate biopsy;&#xD;
&#xD;
          -  Men who are willing to participate in the study;&#xD;
&#xD;
          -  Subjects must freely sign informed consent to enroll in the study;&#xD;
&#xD;
          -  Assessing eligibility: eligibility for the study will be assessed, based upon the&#xD;
             above criteria, by the participating urologist at the time of consultation.&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Men who have had previous treatment for PCa including radiation, cryoablation,&#xD;
             chemotherapy, surgery, high intensity focused ultrasound (HIFU), laser therapy or&#xD;
             hormone therapy;&#xD;
&#xD;
          -  Men who have had previous non-pharmacological invasive or minimally invasive treatment&#xD;
             for benign prostatic hypertrophy (BPH) (i.e., TURP, TUMPT, WIT, TUNA, etc);&#xD;
&#xD;
          -  standard pharmacological treatment of BPH is allowable&#xD;
&#xD;
          -  Men who are mentally impaired and cannot give written consent;&#xD;
&#xD;
          -  Men with anomalies of the rectum.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Polascik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn Nightingale, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fredrica Gallack, BS</last_name>
    <phone>919-681-5557</phone>
    <email>fredrica.gallack@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adi Molvin</last_name>
    <phone>919-681-4990</phone>
    <email>adi.molvin@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fredrica Gallack, BS</last_name>
      <phone>919-681-5557</phone>
      <email>fredrica.gallack@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Polascik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transrectal Ultrasound</keyword>
  <keyword>Prostate biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

